Trial reportJAMA1990
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Trial report in JAMA, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000599. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cholesterol-Lowering Atherosclerosis Study (CLAS)
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 489 citations in OpenAlex.
- Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.Circulation · 2020Pooled it
- Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2000Guideline
- The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).American heart journal · 2011 · on this mapTrial
- The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study.The Clinical investigator · 1994Trial
- Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.International journal of cardiac imaging · 1992Trial
- High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels.American journal of preventive cardiology · 2025Review
- Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.European journal of clinical investigation · 2025Review
- Atherosclerosis: Making a U Turn.Annual review of medicine · 2020Review
- Management and Prevention of Saphenous Vein Graft Failure: A Review.Cardiology and therapy · 2017Review
- Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization.Scientific reports · 2017Article
- All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.Data in brief · 2016Article
- High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties.Molecular metabolism · 2016Review
- Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.Indian journal of clinical biochemistry : IJCB · 2016Review
- Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery.Cardiovascular diagnosis and therapy · 2015Article
- Correlation analysis between serum lipoprotein (a) and the incidence of aortic valve sclerosis.International journal of clinical and experimental medicine · 2015Article
- High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.Circulation research · 2014Review
- Niacin activates the PI3K/Akt cascade via PKC- and EGFR-transactivation-dependent pathways through hydroxyl-carboxylic acid receptor 2.PloS one · 2014Article
- GPR109A and vascular inflammation.Current atherosclerosis reports · 2013Review
- HDL cholesterol and cardiovascular outcomes: what is the evidence?Current cardiology reports · 2013Review
- Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.PloS one · 2013Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects. Two-year results (CLAS-I) showed decreased atherosclerosis progression and increased regression. We now describe a subgroup of 103 subjects treated for 4 years (CLAS-II). Changes in blood lipid, lipoprotein-cholesterol, and apolipoprotein levels were maintained, and at 4 years significantly more drug-treated subjects demonstrated nonprogression (52% drug- vs 15% placebo-treated) and regression (18% drug- vs 6% placebo-treated) in native coronary artery lesions. Significantly fewer drug-treated subjects developed new lesions in native coronary arteries (14% drug- vs 40% placebo-treated) and bypass grafts (16% drug- vs 38% placebo-treated). These results confirm CLAS-I findings and indicate that regression can continue for 4 years. They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects.
Indexed as
Identifiers
2243429W2089648098What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.